A recent European multicentre case series of 28 patients with oral Crohn's disease included ten who were commenced on anti-TNF therapy.7 Nine of these patients achieved disease remission with anti-TNF therapy (infliximab or adalimumab), and in another, adalimumab achieved disease remission but had to be stopped due to side effects. This evidence concerns the gene TNF and Crohn disease.